NETSPOT Drug Patent Profile
✉ Email this page to a colleague
When do Netspot patents expire, and what generic alternatives are available?
Netspot is a drug marketed by Aaa Usa Inc and is included in one NDA. There is one patent protecting this drug.
This drug has thirty-two patent family members in nineteen countries.
The generic ingredient in NETSPOT is gallium dotatate ga-68. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the gallium dotatate ga-68 profile page.
DrugPatentWatch® Generic Entry Outlook for Netspot
Netspot was eligible for patent challenges on June 1, 2020.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be August 10, 2032. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for NETSPOT
International Patents: | 32 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 5 |
Drug Prices: | Drug price information for NETSPOT |
What excipients (inactive ingredients) are in NETSPOT? | NETSPOT excipients list |
DailyMed Link: | NETSPOT at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for NETSPOT
Generic Entry Date for NETSPOT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for NETSPOT
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Hoag Memorial Hospital Presbyterian | Phase 2 |
RayzeBio, Inc. | Phase 2 |
Assistance Publique - Hôpitaux de Paris | Phase 3 |
US Patents and Regulatory Information for NETSPOT
NETSPOT is protected by one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of NETSPOT is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting NETSPOT
Process for the preparation of complexes of .sup.68Ga
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aaa Usa Inc | NETSPOT | gallium dotatate ga-68 | POWDER;INTRAVENOUS | 208547-001 | Jun 1, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for NETSPOT
When does loss-of-exclusivity occur for NETSPOT?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 12297008
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 2014003336
Estimated Expiration: ⤷ Try a Trial
Patent: 2020011908
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 44145
Estimated Expiration: ⤷ Try a Trial
Patent: 45484
Estimated Expiration: ⤷ Try a Trial
China
Patent: 3889930
Estimated Expiration: ⤷ Try a Trial
Colombia
Patent: 20857
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 42017
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 42017
Estimated Expiration: ⤷ Try a Trial
Patent: 55168
Estimated Expiration: ⤷ Try a Trial
Patent: 18991
Estimated Expiration: ⤷ Try a Trial
India
Patent: 97CHN2014
Estimated Expiration: ⤷ Try a Trial
Israel
Patent: 0904
Estimated Expiration: ⤷ Try a Trial
Patent: 5849
Estimated Expiration: ⤷ Try a Trial
Patent: 5979
Estimated Expiration: ⤷ Try a Trial
Italy
Patent: 20110180
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 61610
Estimated Expiration: ⤷ Try a Trial
Patent: 14524423
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 0081
Estimated Expiration: ⤷ Try a Trial
Patent: 14001691
Estimated Expiration: ⤷ Try a Trial
New Zealand
Patent: 2071
Estimated Expiration: ⤷ Try a Trial
Patent: 8281
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 42017
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 42017
Estimated Expiration: ⤷ Try a Trial
Russian Federation
Patent: 05090
Estimated Expiration: ⤷ Try a Trial
Patent: 14109381
Estimated Expiration: ⤷ Try a Trial
Patent: 16144237
Estimated Expiration: ⤷ Try a Trial
Patent: 20120802
Estimated Expiration: ⤷ Try a Trial
South Africa
Patent: 1401789
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 60231
Estimated Expiration: ⤷ Try a Trial
Patent: 35581
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering NETSPOT around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Poland | 2742017 | ⤷ Try a Trial | |
Brazil | 112014003336 | processo para a preparação de complexos de 68ga | ⤷ Try a Trial |
Russian Federation | 2020120802 | СПОСОБ ПОЛУЧЕНИЯ КОМПЛЕКСОВ 68Ga | ⤷ Try a Trial |
Israel | 230904 | תהליך להכנת קומפלקסים של גאליום -68 (Process for the preparation of complexes of 68ga) | ⤷ Try a Trial |
New Zealand | 622071 | Process for the preparation of complexes of 68ga. | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |